Caribou Biosciences Announces Strategic Alternatives Review, Discontinues Vispa-Cel And CB-011 CAR-T Programs, Cuts Workforce; Had $113.8M Cash At June 30

Benzinga Newsdesk www.benzinga.com Negative 94.8%

Neg 94.8% Neu 0% Pos 0%

Comments

No comments yet. Be the first!